Literature DB >> 23964189

Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review.

Saba Al Rashaed1, Abdulaziz Rushood.   

Abstract

A case report of a 52 year old male who received intravitreal bevacizumab and developed culture positive endophthalmitis. Vitreous culture indicated that endophthalmitis was caused by Staphylococcus epidermidis. The patient was initially managed with intravitreal injection of ceftazidime and vancomycin, followed by pars plana lensectomy, pars plana vitrectomy with intravitreal injection of 1 mg/0.1 ml vancomycin, 2.25 mg/0.1 ml ceftazidime, 5 mg/0.1 ml fortified amphotericin-B and 4 mg/0.1 ml dexamethasone. Postoperatively the patient improved significantly. However, vision improved from hand motion to counting fingers secondary to severe retinal ischemia. Acute endophthalmitis can develop after intravitreal bevacizumab injections and cause profound visual loss. A review of literature was also performed for similar cases.

Entities:  

Keywords:  Bevacizumab; Endophthalmitis; Infection; Pars plana vitrectomy; Staphylococcus; Visual loss

Year:  2012        PMID: 23964189      PMCID: PMC3729925          DOI: 10.1016/j.sjopt.2012.04.002

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  36 in total

1.  Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion.

Authors:  Paul B Greenberg; Adam Martidis; Adam H Rogers; Jay S Duker; Elias Reichel
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

2.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

3.  Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema.

Authors:  John O Mason; Michael A Albert; Rachel Vail
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

4.  Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis.

Authors:  M G Speaker; F A Milch; M K Shah; W Eisner; B N Kreiswirth
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

5.  Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.

Authors:  David R Fintak; Gaurav K Shah; Kevin J Blinder; Carl D Regillo; John Pollack; Jeffrey S Heier; Hussein Hollands; Sanjay Sharma
Journal:  Retina       Date:  2008 Nov-Dec       Impact factor: 4.256

6.  Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.

Authors:  Sanjeewa S Wickremasinghe; Kira Michalova; Jagjit Gilhotra; Robyn H Guymer; C Alex Harper; Tien Y Wong; Salmaan Qureshi
Journal:  Ophthalmology       Date:  2008-07-31       Impact factor: 12.079

7.  Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection.

Authors:  O Artunay; E Yuzbasioglu; R Rasier; A Sengül; H Bahcecioglu
Journal:  Eye (Lond)       Date:  2009-12       Impact factor: 3.775

8.  Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Authors:  Jeffrey S Heier; Andrew N Antoszyk; Peter Reed Pavan; Steven R Leff; Philip J Rosenfeld; Thomas A Ciulla; Richard F Dreyer; Ronald C Gentile; Judy P Sy; Gary Hantsbarger; Naveed Shams
Journal:  Ophthalmology       Date:  2006-02-14       Impact factor: 12.079

9.  Bevacizumab (Avastin) for the treatment of neovascular glaucoma.

Authors:  Michael N Chilov; John R Grigg; T Justin Playfair
Journal:  Clin Exp Ophthalmol       Date:  2007-07       Impact factor: 4.207

10.  Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.

Authors:  Shahin Yazdani; Kamran Hendi; Mohammad Pakravan
Journal:  J Glaucoma       Date:  2007-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.